FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:872-875 September 1, 2005 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Reid, I. R. Related Article by Cundy, T. PubMed Citation

Fifty years of steady clinical progress and five years of accelerated basic research in understanding the cellular and molecular biology of the osteoclast have led to the development of two drugs for the treatment of Paget's disease of bone, as reported in this issue of the Journal by Reid and colleagues (pages 898–908) and Cundy and colleagues (pages 918–923). In Paget's disease, as in many other skeletal disorders, the osteoclast is the cellular villain; it literally chews up and spits out the skeleton (see diagram). In the normal adult skeleton, this large, multinucleated cell helps to maintain skeletal homeostasis . . . [Full Text of this Article]

Source Information

Dr. Deftos is a professor of medicine and a physician at the University of California at San Diego and the San Diego Veterans Affairs Medical Center, respectively, and a professor of law at the California Western School of Law, San Diego.

This article has been cited by other articles:

• Ruggiero, S.L., Drew, S.J. (2007). Osteonecrosis of the Jaws and Bisphosphonate Therapy. J. Dent. Res. 86: 1013-1021 [Abstract] [Full Text]  
• CHAFFINS, J. A. (2007). Paget Disease of Bone. radtech 79: 27-40 [Abstract] [Full Text]